Utilising CROs for Effective Planning and Execution of Clinical Development

BioStock Summit—Aixial’s experts, Ashley Hunter, Senior Director of Clinical Operations and Head of Strategic Development and delivery, and Anna Yanaeva, Senior Director for Business Development, led an engaging discussion on the importance of “Utilising CROs for Effective Planning and Execution of Clinical Development.”

At the recent BioStock Summit in Lund, our experts Ashley Hunter and Anna Yanaeva delve into how effectively utilizing CROs can significantly improve the planning, execution, and scalability of clinical trials. They share actionable strategies to navigate the complexities of clinical development, enhance efficiency, and achieve successful outcomes.

Don’t miss out on expert tips and strategies that can help you maximize the value of CRO partnerships for your clinical development journey. Watch the full interview now!

TO GO FURTHER

Utilising CROs for Effective Planning and Execution of Clinical Development

At the recent BioStock Summit in Lund, Aixial’s experts, Ashley Hunter, Senior Director of Clinical Operations and Head of Strategic Development & Delivery, and Anna Yanaeva, Senior Director for Business Development, led an engaging discussion on the importance of “Utilising CROs for Effective Planning and Execution of Clinical Development”.

Writings with molecules and standards as main characters

Clear communication is essential to drug development. At Aixial Group, our experienced medical writers know how to turn complex scientific data into clear, accurate documents. From regulatory protocols to scientific publications, they ensure clarity and compliance at every stage.

Clinical trials – when digital becomes critical

Digitalisation — Clinical trials are essential research studies evaluating medical intervention safety and efficacy, with varying designs and phases aimed at understanding treatment effects and patient experiences…

A phase II basket trial of (IP) in combination with (drug) in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations

Pancreatic cancer is the 12th most common cancer in the world and remains one of the deadliest, with a five-year survival rate of only 13%, despite recent progress.

Atomising cancer

Breakthrough — Radiopharmaceutical therapy represents a novel approach to treating cancer, utilising radioactive atoms to target and destroy malignant cells with precision, without affecting the patient’s healthy tissues. A field in which Aixial has emerged as a pioneer.